References
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
- Nelson HD, Fu R, Zakher B, et al. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US preventive services task force. JAMA. 2019;322(9):868–886. doi: 10.1001/jama.2019.5780.
- Chlebowski RT, Aragaki AK, Pan K. Breast cancer prevention: time for change. J Clin Oncol Oncol Pract. 2021;17(12):709–716. doi: 10.1200/OP.21.00343.
- Medicines and Healthcare products Regulatory Agency Press Release. MHRA authorises enzyme inhibitor Anastrozole to prevent breast cancer in post-menopausal women. 2023 Nov 6. Available from: https://www.gov.uk/government/news/mhra-authorises-enzyme-inhibitor-anastrozole-to-prevent-breast-cancer-in-post-menopausal-women
- Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107(2):167–180. doi:10.1007/s10549-007-9548-1.
- Okwuosa TM, Morgans A, Rhee JW, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14(3):e000082.
- Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916–2946. doi:10.1200/JCO.19.01696.
- NHS England. Tens of thousands of women set to benefit from ‘repurposed’ NHS drug to prevent breast cancer. 2023 Nov 7. Available from: https://www.england.nhs.uk/2023/11/tens-of-thousands-of-women-set-to-benefit-from-repurposed-nhs-drug-to-prevent-breast-cancer/
- Taylor C, McGale P, Probert J, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993–2015: population based observational cohort study. BMJ. 2023;381:e074684. doi:10.1136/bmj-2022-074684.
- Centres for Disease Control and Prevention. United States cancer statistics (USCS). U.S. Cancer statistics breast cancer stat bite. 2023 Jun 23; Available at: https://www.cdc.gov/cancer/uscs/about/stat-bites/stat-bite-breast.htm
- Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA. 2020;324(4):369–380. doi:10.1001/jama.2020.9482.
- Manson JE, Kaunitz AM. Menopause management–getting clinical care back on track. N Engl J Med. 2016;374(9):803–806. doi:10.1056/NEJMp1514242.
- Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing. Cancer J. 2022;28(3):208–223. doi: 10.1097/PPO.0000000000000591.
- Nerattini M, Jett S, Andy C, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer’s disease and dementia. Front Aging Neurosci. 2023;15:1260427. doi:10.3389/fnagi.2023.1260427.
- The Fawcett Society. Menopause and the workplace. 2022. [cited 2023 Oct 2]. Available from: https://www.fawcettsociety.org.uk/Handlers/Download.ashx?IDMF=9672cf45-5f13-4b69-8882-1e5e643ac8a6
- British Medical Association. Challenging the culture on menopause for working doctors. 2020 Aug 22. Available at: https://www.bma.org.uk/media/2913/bma-challenging-the-culture-on-menopause-for-working-doctors-report-aug-2020.pdf